Latest News

• A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3         This is the latest version of CUSP9   (CUSP9v3) This is a very small study so obviously has to be repeated with larger numbers but they have impressive data. Looking at the survival curve for survival, progression free survival at 12 months was 50% which is pretty good. However, of the 5 patients who lived that long, none of them did yet, so there is a tail of the curve that doesn't drop below the 50% survival point.  This is a for a cocktail of repurposed drugs that are easily available, in addition to Temozolomide.
  



• Help Us Better Understand Glioblastoma Multiforme         This is from our friends at Pinpoint Patient Recruiting.  They do surveys and interviews to help drug companies learn about the needs of the Glioblastoma patients and caregivers.  They give us (the Musella Foundation) a donation, and you get $75 for taking the survey. Everyone wins and you help these companies understand our needs better!
  



• A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3         This is the results of the CUSP9v3 trial, and they are impressive. It was not controlled and is relatively small, but for patients with recurrent glioblastoma, the progression free survival rate at 12 months was 50%.    This is a combination of older non cancer drugs, along with Temodar. All are easily available and relatively safe. May be worth trying both for newly diagnosed and recurrent Glioblastoma.
  



• Musella Foundation Copay Program now closed to new and renewal patients         We had a good run but ran out of money.  We gave out 280 grants so far this year to patients, each up to $5,000 - which adds up to an amazing $1,395,000 (if they all use their entire grant - if not, we reclaim the money and recycle it for the next patients!)  
  



• Hackensack Meridian Children's Health Children's Cancer Institute Now a Member of the Pacific Pediatric Neuro-Oncology Consortium (PNOC)        
  This is exciting news - I am a big fan of Hackensack Meridian Children's Cancer Institute as they once treated a relative of mine for a glioblastoma. And I love PNOC - they are involved with the most important trials for pediatric brain tumors.  This collaboration will bring these trials to New Jersey and upstate NY!   NYU in Manhattan is also a participating center!
  See https://pnoc.us/participating-sites/ for all of the sites!